| scholarly article | Q13442814 |
| P50 | author | Cinzia Boselli | Q63244417 |
| Sergio Schinelli | Q89878777 | ||
| Mayra Paolillo | Q41552599 | ||
| P2093 | author name string | Sergio Schinelli | |
| Cinzia Boselli | |||
| P2860 | cites work | Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. | Q51392451 |
| Temozolomide resistance in glioblastoma multiforme | Q91792247 | ||
| Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma | Q38737954 | ||
| Advances in the molecular genetics of gliomas - implications for classification and therapy | Q38777058 | ||
| Integrins in glioblastoma: Still an attractive target? | Q38920829 | ||
| Novel vaccines for glioblastoma: clinical update and perspective | Q39043417 | ||
| In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles | Q39445917 | ||
| Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines | Q40135506 | ||
| Integrins and Exosomes, a Dangerous Liaison in Cancer Progression | Q41552575 | ||
| Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment | Q41845603 | ||
| Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells | Q42182089 | ||
| Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. | Q42776089 | ||
| Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma. | Q42778369 | ||
| Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. | Q45396446 | ||
| Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. | Q46198099 | ||
| Diffuse Infiltrating Oligodendroglioma and Astrocytoma. | Q46522806 | ||
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial | Q46600515 | ||
| Functional network analysis of gene-phenotype connectivity associated with temozolomide | Q47258480 | ||
| Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response | Q47270129 | ||
| Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. | Q47565868 | ||
| Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients | Q47594755 | ||
| Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. | Q47594798 | ||
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. | Q48588707 | ||
| Extended field stereotactic radiosurgery for recurrent glioblastoma | Q48768943 | ||
| Immunotherapy: CAR T cells in glioblastoma | Q50027720 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors | Q26765289 | ||
| Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates | Q27007519 | ||
| Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma | Q27016552 | ||
| Structural and functional features of central nervous system lymphatic vessels | Q27316769 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma | Q28087306 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | Q33561644 | ||
| History and current state of immunotherapy in glioma and brain metastasis | Q33656811 | ||
| Potential of solid lipid nanoparticles in brain targeting | Q34010210 | ||
| Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma | Q34506962 | ||
| Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. | Q34627868 | ||
| The cellular and molecular basis of hyperthermia | Q34721242 | ||
| Recent progress in the battle between oncolytic viruses and tumours | Q36315580 | ||
| Basic concepts of immunology and neuroimmunology | Q36525975 | ||
| Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles | Q36625112 | ||
| Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. | Q37279893 | ||
| An update in the use of antibodies to treat glioblastoma multiforme | Q37329927 | ||
| Glioblastoma: Overview of Disease and Treatment | Q37441791 | ||
| Glioma virus therapies between bench and bedside | Q37580510 | ||
| Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy | Q37741143 | ||
| Immunotherapy for the treatment of glioblastoma | Q37980026 | ||
| Malignant glioma: lessons from genomics, mouse models, and stem cells | Q37998643 | ||
| Impact of somatic copy number alterations on the glioblastoma miRNome: miR-4484 is a genomically deleted tumour suppressor. | Q38435063 | ||
| Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma | Q38453759 | ||
| Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? | Q38534723 | ||
| Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells | Q38694765 | ||
| Nanoparticles: Novel vehicles in treatment of Glioblastoma | Q38706430 | ||
| Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model | Q38733637 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | glioblastoma | Q282142 |
| P577 | publication date | 2018-01-16 | |
| P1433 | published in | Brain Sciences | Q27724596 |
| P1476 | title | Glioblastoma under Siege: An Overview of Current Therapeutic Strategies | |
| P478 | volume | 8 |
| Q92622822 | 'Characterization of monoclonal antibodies generated to the 287-302 amino acid loop of the human epidermal growth factor receptor' |
| Q52644558 | An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective. |
| Q60949934 | Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen |
| Q90056969 | Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors |
| Q57456667 | Combination therapy to checkmate Glioblastoma: clinical challenges and advances |
| Q92326358 | Current Therapeutic Strategies for Glioblastoma |
| Q91344698 | Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential |
| Q54965858 | Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. |
| Q61809548 | Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells |
| Q64066303 | Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy |
| Q89659857 | Lanthanide-Doped SPIONs Bioconjugation with Trastuzumab for Potential Multimodal Anticancer Activity and Magnetic Hyperthermia |
| Q90472252 | Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors |
| Q96155628 | Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma |
| Q99241324 | Organoid models of glioblastoma: advances, applications and challenges |
| Q93088944 | Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma |
| Q92862398 | Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles |
| Q58596799 | Prosaposin promotes the proliferation and tumorigenesis of glioma through toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway |
| Q96950776 | Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples |
| Q64058757 | Rat Glioma Cell-Based Functional Characterization of Anti-Stress and Protein Deaggregation Activities in the Marine Carotenoids, Astaxanthin and Fucoxanthin |
| Q57031212 | Role of extracellular matrix and microenvironment in regulation of tumor growth and LAR-mediated invasion in glioblastoma |
| Q93155628 | SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells |
| Q99591448 | Targeting Receptors on Cancer Cells with Protein Toxins |
| Q90195094 | The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior |
| Q90232049 | Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents |
Search more.